Evidence map›Paper›PMID 31557208›Full record

ArticlePloS one2019

Rollout of ShangRing circumcision with active surveillance for adverse events and monitoring for uptake in Kenya.

Elijah Odoyo-June, Nandi Owuor, Saida Kassim, Stephanie Davis, Kawango Agot, Kennedy Serrem, George Otieno, Quentin Awori, Jonas Hines, Carlos Toledo and 7 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 2 countries.

Elijah Odoyo-JuneDivision of Global HIV & TB, U.S. Centers for Disease Control and Prevention, Kisumu, Kenya.ORCID 0000-0002-1370-2306
Nandi OwuorJhpiego, Nairobi, Kenya.
Saida KassimMOH-NASCOP National STD/AIDS Control Program, Ministry of Health, Nairobi, Kenya.
Stephanie DavisDivision of Global HIV & TB, U.S. Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Kawango AgotImpact Research and Development Organization, Kisumu, Kenya.
Kennedy SerremMOH-NASCOP National STD/AIDS Control Program, Ministry of Health, Nairobi, Kenya.
George OtienoUniversity of Maryland Baltimore, Migori, Kenya.
Quentin AworiPopulation Council/Engender Health, Nairobi, Kenya.
Jonas HinesDivision of Global HIV & TB, U.S. Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Carlos ToledoDivision of Global HIV & TB, U.S. Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Catey LaubeJhpiego, Nairobi, Kenya.
Christine KisiaWHO Kenya Office, Nairobi, Kenya.
Appolonia AokoDivision of Global HIV & TB, U.S. Centers for Disease Control and Prevention, Kisumu, Kenya.
Vincent OjiamboUSAID-Kenya East Africa, Nairobi, Kenya.
Zebedee MwandiJhpiego, Nairobi, Kenya.
Ambrose JumaMOH-NASCOP National STD/AIDS Control Program, Ministry of Health, Nairobi, Kenya.
Bartilol KigenMOH-NASCOP National STD/AIDS Control Program, Ministry of Health, Nairobi, Kenya.
Ministry of Health · KECenters for Disease Control and Prevention · USCenters for Disease Control and Prevention · KEImpact Research and Development Organization · KEUniversity of Maryland, Baltimore · US

Funding

PEPFAR
6 · The paper itself

Abstract

introductionSince 2011, Kenya has been evaluating ShangRing device for use in its voluntary medical male circumcision (VMMC) program according to World Health Organization (WHO) guidelines. Compared to conventional surgical circumcision, the ShangRing procedure is shorter, does not require suturing and gives better cosmetic outcomes. After a pilot evaluation of ShangRing in 2011, Kenya conducted an active surveillance for adverse events associated with its use from 2016-2018 to further assess its safety, uptake and to identify any operational bottlenecks to its widespread use based on data from a larger pool of procedures in routine health care settings.

methodsFrom December 2017 to August 2018, HIV-negative VMMC clients aged 13 years or older seeking VMMC at six sites across five counties in Kenya were offered ShangRing under injectable local anesthetic as an alternative to conventional surgical circumcision. Providers described both procedures to clients before letting them make a choice. Outcome measures recorded for clients who chose ShangRing included the proportions who were clinically eligible, had successful device placement, experienced adverse events (AEs), or failed to return for device removal. Clients failing to return for follow up were sought through phone calls, text messages or home visits to ensure removal and complete information on adverse events.

resultsOut of 3,692 eligible clients 1,079 (29.2%) chose ShangRing; of these, 11 (1.0%) were excluded due to ongoing clinical conditions, 17 (1.6%) underwent conventional surgery due to lack of appropriate device size at the time of the procedure, 97.3% (1051/1079) had ShangRing placement. Uptake of ShangRing varied from 11% to 97% across different sites. There was one severe AE, a failed ShangRing placement (0.1%) managed by conventional wound suturing, plus two moderate AEs (0.2%), post removal wound dehiscence and bleeding, that resolved without sequelae. The overall AE rate was 0.3%. All clients returned for device removal from fifth to eleventh day after placement.

conclusionShangRing circumcision is effective and safe in the Kenyan context but its uptake varies widely in different settings. It should be rolled out under programmatic implementation for eligible males to take advantage of its unique benefits and the freedom of choice beyond conventional surgical MMC. Public education on its availability and unique advantages is necessary to optimize its uptake and to actualize the benefit of its inclusion in VMMC programs.

Indexed as

Epidemiological MonitoringAdolescentAdultCircumcision, MaleHumansKenyaMaleMiddle AgedPatient Acceptance of Health CarePatient SatisfactionPostoperative ComplicationsProgram EvaluationVoluntary ProgramsYoung Adult

Identifiers

PMID31557208
PMCPMC6762105
OpenAlexW2975925336

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.